-

Retractable Technologies, Inc. Results for the Periods Ended September 30, 2026

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $14.1 million for the third quarter of 2026 and an operating loss of $4.1 million for the period, as compared to total net sales for the same period last year of $10.1 million and an operating loss of $3.7 million. For the first nine months of the year, net sales were $28.5 million and operating losses were $15.5 million as compared to 2025 net revenues of $28.8 million and operating losses of $13.5 million.

In 2026, purchasing patterns have been more consistent with historical trends, with the majority of flu season sales occurring in the third quarter. In contrast, in 2025, flu season sales were unusually high in the second quarter, affecting comparability.

We continue to lessen the financial impact of tariffs by producing certain products domestically and strategically ordering certain products from our Chinese suppliers. Domestic production comprised 40.3% of the units manufactured during the first nine months of 2026. Additionally, a reduction in force in April 2026 has resulted in cost savings.

Our net losses for the three and nine months ended September 30, 2026 were $(2.4) million and $(3.8) million, respectively, including a $6.4 million gain on the sale of equity securities during the nine-month period ended September 30, 2026.

Retractable reports the following results of operations for the three and nine months ended September 30, 2026 and 2025, respectively. Further details concerning the results of operations, as well as other matters, are available in Retractable’s Form 10-Q filed on November 16, 2026 with the U.S Securities and Exchange Commission.

Comparison of Three Months Ended September 30, 2026 and September 30, 2025

Domestic net sales accounted for 90.3% and 91.1% of total net sales for the three months ended September 30, 2026 and 2025, respectively. Domestic net sales increased 38.9%, while domestic unit sales increased 59.5%, primarily due to the timing of EasyPoint® product orders from certain customers, which can fluctuate between periods based on customer purchasing patterns. The higher growth in unit sales relative to net sales reflects a shift in product mix, as EasyPoint® products, which traditionally carry a lower average selling price than syringe products, represented a greater proportion of domestic unit sales. Domestic unit sales represented 81.6% of total unit sales for the three months ended September 30, 2026, compared to 83.9% for the same period in 2025.

International net sales for the three months ended September 30, 2026 increased 52.2% compared to the same period in 2025. The increase in international sales was primarily driven by an increase in EasyPoint® needle sales. Traditionally, international sales carry lower average selling prices compared to our domestic sales. There remains uncertainty regarding the timing of future international orders.

Overall, unit sales increased 64.0% due to an increase in EasyPoint® needle sales.

Cost of manufactured product increased 69.9% compared to the same period last year primarily due to an increase in units sold during the period. Royalty expense increased 29% due to the increase in gross sales.

Tariffs may impact our costs in future periods. Approximately $260 thousand was spent on tariff expenses in the third quarter of 2026. The continued reduction in tariff costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic production. These costs are included in Cost of manufactured product.

Operating expenses decreased 18.9% primarily due to lower gross wages in the Sales and Marketing department and lower donation and credit loss expenses within General and administrative expenses.

The loss from operations was $4.1 million for the three months ended September 30, 2026 compared to a loss from operations of $3.7 million in the three months ended September 30, 2025. The increase in loss from operations was primarily driven by lower gross margin in the current period, reflecting changes in domestic and international product sales mix, partially offset by lower operating expenses.

The unrealized loss on debt and equity securities was $150 thousand for the third quarter of 2026 due to the decreased market values of those securities. There was no realized gain or loss from the sale of debt and equity securities in the third quarter of 2026.

The provision for income taxes was $1.3 thousand for the three months ended September 30, 2026 and $1.7 thousand for the three months ended September 30, 2025.

Comparison of Nine Months Ended September 30, 2026 and September 30, 2025

Domestic net sales accounted for 86.2% and 87.1% of total net sales for the nine months ended September 30, 2026 and 2025, respectively. Domestic net sales decreased 2.1%, while domestic unit sales increased 6.4%, reflecting a shift in product mix toward EasyPoint® needles relative to syringes. As EasyPoint® needles traditionally have a lower average selling price than syringes, the change in product mix contributed to the decrease in domestic net sales. Domestic unit sales represented 76.6% of total unit sales for the nine months ended September 30, 2026, compared to 78.0% for the same period last year.

International net sales for the nine months ended September 30, 2026 increased 5.5% compared to the same period in 2025 primarily due to an increase in EasyPoint® sales. Traditionally, international sales carry lower average selling prices compared to our domestic sales. There remains uncertainty regarding the timing of future international orders.

Overall, unit sales increased 8.3%.

Cost of manufactured product increased 6.8% compared to the same period last year primarily due to an increase in units sold. The shift in product mix towards lower-margin products also contributed to the decrease in gross margin. Royalty expense remained consistent with the prior period.

Tariffs may impact our costs in future periods. Approximately $318 thousand was spent on tariff expenses in the first nine months of 2026. The continued reduction in tariff costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic production. These costs are included in Cost of manufactured product.

Operating expenses remained consistent with the prior period.

The loss from operations was $15.5 million compared to a loss of approximately $13.5 million for the same period last year. The increased loss from operations was primarily driven lower gross margin, reflecting changes in domestic and international product sales mix.

The unrealized loss on debt and equity securities was $137 thousand for the nine months ended September 30, 2026 due to the decreased market values of those securities. The realized gain from the sale of equity securities was $6.4 million in the first nine months of 2026.

The provision for income taxes was $5.0 thousand as compared to a benefit for income taxes of $289 thousand for the same period in 2025. The change is primarily due to a decrease in the net loss in the current period.

ABOUT RETRACTABLE

Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.

For more information on Retractable, visit its website at www.retractable.com.

Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements.

Factors that could cause or contribute to such differences include, but are not limited to: tariffs; oil prices; material changes in demand; Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.

Contacts

Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief Accounting Officer

Retractable Technologies, Inc.

NYSEAM:RVP

Release Versions

Contacts

Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief Accounting Officer

More News From Retractable Technologies, Inc.

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning July 1, 2026 through September 30, 2026. The dividends will be paid on October 22, 2026...

Retractable Technologies, Inc. Supports Senator Blackburn’s ONSHORE Manufacturing Act

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announces its support for Senator Marsha Blackburn’s ONSHORE Manufacturing Act, legislation aimed at strengthening domestic production of critical medical supplies. The legislation would provide tax incentives for U.S. manufacturing, including investments in advanced manufacturing equipment and facility modernization. “The ONSHORE Manufacturing Act is the spark American manufacturers need to...

Retractable Technologies, Inc. Results for the Periods Ended June 30, 2026

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.2 million for the second quarter of 2026 and an operating loss of $5.1 million for the period, as compared to total net sales for the same period last year of $10.4 million and an operating loss of $5.1 million. For the first half of the year, net sales were $14.4 million and operating losses were $11.3 million as compared to 2025 net revenues of $18.7 million and operating loss...
Back to Newsroom